KDIGO is updating The 2021 Clinical Practice Guideline for the Management of Glomerular Diseases on an ongoing, chapter-by-chapter basis.
The KDIGO 2024 Clinical Practice Guideline for the Management of IgA Nephropathy (IgAN) and IgA Vasculitis (IgAV) is available for public review through Monday, September 30. The update takes into consideration evidence from randomized controlled trials published through April 2023. KDIGO invites you to review this chapter update and share your candid comments and suggestions via the feedback survey on the KDIGO IgAN/IgAV Guideline website. A final revised version will be prepared for publication based on the feedback received during this open comment period.
The KDIGO 2024 Clinical Practice Guideline for the Management of Antineutrophilic Cytoplasmic Antibody (ANCA)-Associated Vasculitis was published in the March issue of Supplement to Kidney International, with an Executive Summary in the main pages of the journal. Visit the KDIGO ANCA Vasculitis Guideline website to download the ANCA Vasculitis Guideline and for additional resources.
The KDIGO 2024 Clinical Practice Guideline for the Management of Lupus Nephritis is the first of these updates. The guideline was published in the January 2024 issue of Supplements to Kidney International, with an Executive Summary in the main pages of the journal. Visit the KDIGO Lupus Nephritis website to download the Lupus Nephritis Guideline and additional resources.
The KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases was published in the October 2021 issue of Supplements to Kidney International with an Executive Summary in the main pages of the journal. This guideline is the most extensive in KDIGO history, organized into eleven chapters, ten of which cover a specific primary or secondary glomerular disease or group of diseases. The first chapter is an extensive review of general management principles that should be considered for patients with any type of glomerular disease. All topics will be reassessed on a continuous basis and will be updated based on the availability of new evidence that may alter a guideline statement in the previous version.
Brad Rovin, MD (United States), and Jürgen Floege, MD (Germany) co-chaired the guideline chapter updates and the 2021 KDIGO Glomerular Diseases Guideline.
61st ERA Congress Highlights on Complement-Mediated Kidney Disease with Marina Vivarelli (2024)
61st ERA Congress Highlights on IgA Nephropathy with Jonathan Barratt (2024)
CJASN
How I Treat: Focal Segmental Glomerulosclerosis (FSGS) (2022)
How I Treat: Steroid-Sensitive Nephrotic Syndrome in Children (SSNS) (2002)
How I Treat: Lupus Nephritis (LN) (2022)
How I Treat: Rituximab in the Frail and Elderly with Severe ANCA-Associated GN (2022)
How I Treat: IgA Nephropathy (IgAN)(2022)
KDIGO-Arkana 2022 Pathology Slide Set based on the KDIGO 2021 GD Guideline
Glomerular Diseases Guideline ASN Kidney Week 2023 Highlights in IgA Nephropathy
KDIGO sat down with Dr. Rovin at ASN Kidney Week 2023 to get his insights on the changing landscape in managing and treating glomerular diseases and the latest in IgA Nephropathy. Watch the video below.
Learn more about recent trials and related publications shared at ASN Kidney Week by clicking here.
DISCLAIMER: USE OF THE CLINICAL PRACTICE GUIDELINES
This Clinical Practice Guideline is based upon the best information available at the time of publication. The recommendations are designed to provide information and assist decision-making. They are not intended to define a standard of care, and should not be construed as one. Neither should they be interpreted as prescribing an exclusive course of management. Variations in practice will inevitably and appropriately occur when clinicians take into account the needs of individual patients, available resources, and limitations unique to an institution or type of practice. Every health care professional making use of this Guideline is responsible for evaluating the appropriateness of applying them in the setting of any particular clinical situation. The recommendations for research contained within this document are general and do not imply a specific protocol.
